1. Home
  2. CRSP vs KGS Comparison

CRSP vs KGS Comparison

Compare CRSP & KGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • KGS
  • Stock Information
  • Founded
  • CRSP 2013
  • KGS 2011
  • Country
  • CRSP Switzerland
  • KGS United States
  • Employees
  • CRSP N/A
  • KGS N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • KGS
  • Sector
  • CRSP Health Care
  • KGS
  • Exchange
  • CRSP Nasdaq
  • KGS Nasdaq
  • Market Cap
  • CRSP 3.4B
  • KGS 3.8B
  • IPO Year
  • CRSP 2016
  • KGS 2023
  • Fundamental
  • Price
  • CRSP $36.99
  • KGS $37.61
  • Analyst Decision
  • CRSP Buy
  • KGS Strong Buy
  • Analyst Count
  • CRSP 19
  • KGS 11
  • Target Price
  • CRSP $74.35
  • KGS $41.45
  • AVG Volume (30 Days)
  • CRSP 1.6M
  • KGS 1.2M
  • Earning Date
  • CRSP 05-07-2025
  • KGS 03-05-2025
  • Dividend Yield
  • CRSP N/A
  • KGS 4.39%
  • EPS Growth
  • CRSP N/A
  • KGS 94.67
  • EPS
  • CRSP N/A
  • KGS 0.56
  • Revenue
  • CRSP $37,314,000.00
  • KGS $1,159,311,000.00
  • Revenue This Year
  • CRSP $49.76
  • KGS $18.60
  • Revenue Next Year
  • CRSP $257.28
  • KGS $6.04
  • P/E Ratio
  • CRSP N/A
  • KGS $66.21
  • Revenue Growth
  • CRSP N/A
  • KGS 36.33
  • 52 Week Low
  • CRSP $36.52
  • KGS $24.84
  • 52 Week High
  • CRSP $68.39
  • KGS $50.43
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 34.31
  • KGS 43.69
  • Support Level
  • CRSP $40.41
  • KGS $37.67
  • Resistance Level
  • CRSP $42.72
  • KGS $39.50
  • Average True Range (ATR)
  • CRSP 1.73
  • KGS 1.38
  • MACD
  • CRSP -0.55
  • KGS 0.32
  • Stochastic Oscillator
  • CRSP 0.80
  • KGS 70.47

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About KGS Kodiak Gas Services Inc.

Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Compression Operations and Other Services. Compression Operations consist of operating company-owned and customer-owned compression infrastructure for customers, pursuant to fixed-revenue contracts to enable the production, gathering and transportation of natural gas and oil. Other Services consist of a full range of contract services to support the needs of customers, including station construction, maintenance and overhaul and other ancillary time and material-based offerings.

Share on Social Networks: